$INAB News

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio Announces Publication Of Peer-Reviewed Clinical Data From Phase 1 Trial Of INB-200 In The Journal Of Clinical Oncology

IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

IN8bio Presents New Translational Data Of Its DeltEx DRI Platform At ISCT 2026 Annual Meeting And ASGCT 2026 Annual Meeting

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target